Coeliac disease enteropathy and symptoms may be aggravated by angiotensin receptor blockers in patients on a gluten-free diet

Neil O'Morain\textsuperscript{1} $\diamondsuit$ | Eileen Shannon\textsuperscript{1} $\diamondsuit$ | John McManus\textsuperscript{1} | Vanessa Warner\textsuperscript{1} | Hilary Leeson\textsuperscript{1} $\diamondsuit$ | Helen O'Donovan\textsuperscript{1} | Brian Egan\textsuperscript{2} | Valerie Byrnes\textsuperscript{1}

\textsuperscript{1}Department of Gastroenterology, Galway University Hospital, Galway, Ireland
\textsuperscript{2}Department of Gastroenterology, Mayo General Hospital, Castlebar, Ireland

Correspondence
Neil O'Morain, Department of Gastroenterology, Galway University Hospital, Galway, Ireland.
Email: neilmoran@gmail.com

Abstract

Background: Angiotensin receptor blocker-associated enteropathy (ARB-e) is an increasingly recognised clinical entity with symptoms and histological findings identical to coeliac disease (CD). There is evidence to suggest immune-mediated mucosal injury in ARB-e with a high prevalence of DQ2/DQ8; however, as IgA anti-tissue transglutaminase (anti-TTG) is usually negative, an insult other than TTG-mediated injury is suspected. The impact of ARBs on disease activity in patients with CD is not known.

Objective: To assess the effect of ARB exposure on patients with established CD.

Methods: A patient record search of 1142 individual patients attending a dedicated coeliac clinic from 2010 to the present identified 59 patients treated with ARB. Those with CD confirmed by serology (TTG + ve/EMA + ve) and histopathology (Marsh criteria) were included ($n=40$, 0.52%). Data collected included disease duration, compliance with gluten-free diet (GFD), reported symptoms (diarrhoea, weight loss and abdominal pain), surrogate markers of absorption (Vitamin D, Iron, Calcium and Haemoglobin), in addition to anti-TTG titre and histological grade at last follow up. Patients were age and sex-matched in a 1:2 ratio with CD patients not taking ARBs (controls), with comparable rates of disease duration and compliance with GFD.

Results: The ARB and control groups were matched in terms of age (mean 66.2 years) and gender (female 63%). Strict compliance with GFD was reported in 55% and 56%, respectively. Persistent symptoms were reported in 10/40 (25%) of the ARB group compared with 7/82 (9%) of controls ($p=0.0181$). There were lower rates of mucosal healing (Marsh grade 0) in the ARB group (36% $n=11$) compared to controls (55%, $n=33$). There was no significant difference in anti-TTG titres. Surrogate markers of absorption were comparable across the groups, except for Vitamin D which was lower in those taking olmesartan ($p=0.0015$).
Conclusions: ARBs may aggravate the enteropathy and lead to increased symptoms in patients with bone fide diagnosed CD following a GFD.

KEYWORDS
angiotensin receptor blocker, anti-TTG, ARB-enteropathy, coeliac disease, enteropathy, gluten-free diet, MARSH

Key summary
Summarise the established knowledge on this subject
• Angiotensin receptor blocker-associated enteropathy (ARB-e) is an increasingly recognised clinical entity with symptoms and histological findings almost identical to coeliac disease (CD).
• The exact cause of mucosal injury in ARB-e is unknown however there is evidence to suggest immune-mediated mucosal injury in ARB-e with a high prevalence of DQ2/DQ8, however as anti-tissue transglutaminase (TTG) is usually negative, an insult other than TTG-mediated injury is suspected. The impact of ARBs on disease activity in patients with CD is not known.

What are the significance and/or new findings of this study?
• Coeliac patients who take ARBs are more likely to have persistent symptoms and lower rates of mucosal healing than their age-matched coeliac controls. This observation appears to be independent of TTG mediated injury, akin to that reported in non-coeliac populations.
• ARB use in patients with established coeliac disease may confound the interpretation of clinical and histological response to a gluten-free diet.

INTRODUCTION
Angiotensin receptor blocker-associated enteropathy (ARB-e) is an increasingly recognised clinical entity that presents insidiously with symptoms and histological findings almost identical to coeliac disease (CD). The association between angiotensin receptor antagonist use and enteropathy was first described in 2012 in a case series which identified 22 patients who developed a severe sprue-like enteropathy with concomitant olmesartan medoxomil® therapy. These patients developed chronic diarrhoea and weight loss, however had negative coeliac serology despite evidence of mucosal injury and did not respond to a gluten-free diet. This enteropathy was noted to be transient and resolved completely upon removal of the offending medication. Since then, a host of publications have appeared both confirming this ARB-e as a new clinical entity2–9 but also implicating other ARBs, though perhaps not as severe as olmesartan, but nonetheless demonstrating a class effect.10–16 Many patients with an initial diagnosis of ‘serology negative’ CD were reclassified as having an ARB-e.11,12,17–21 While the risk of developing ARB-e in individuals taking ARB medication is extremely low,22,23 the prevalence of ARB-e is likely to be underreported.17

The pathophysiology of ARB-e and indeed the exact cause of mucosal injury remains largely unexplained. There is evidence to suggest an immune-mediated process with a higher prevalence of the HLA-DQ2/DQ8 gene alleles in affected individuals compared to the baseline population.1–3 However, as anti-tissue transglutaminase (anti-TTG) is usually negative4,24 an insult other than, or in combination with, TTG-mediated injury is suspected. Potential coeliac markers (anti-TG2 deposits and specific intraepithelial leukocytes) have been identified in a subset of these patients, which have been shown to persist following withdrawal of ARB, suggesting affected individuals may indeed carry an underlying susceptibility.25,26 There is generally a relatively long period (months-years) from initiation of the drug to the manifestation of disease, with longer durations to diagnosis associated with more severe presentations.7 This might suggest that the pathological process is cell-mediated rather than a hypersensitivity reaction.1,4,17,22

Most reported cases to date have demonstrated negative coeliac serological markers, however, transient increases in anti-TTG titres at symptom onset have been documented, indicating that positive markers do not completely rule ARB-e.27 While the association between ARBs and enteropathy is now well recognised, there is a paucity of data regarding the impact of ARBs on disease activity in patients with established CD.28 Indeed, established coeliac patients on an ARB with ongoing symptoms or histologic injury, in spite of strict adherence to a gluten-free diet (GFD) may be misdiagnosed with refractory CD. We have observed the presence of ‘pseudo refractory’ CD in two such patients while on ARB therapy. Symptoms and histological injury resolved completely following withdrawal of ARB therapy. In light of this, we elected to identify a cohort of patients with established CD exposed to ARBs and review the clinical, biochemical and histological markers of disease severity when compared to coeliac patients not exposed to this class of drugs.
METHODS

Patient selection

This was a retrospective single centre case-control study. A patient record search of 1142 individual patients attending a dedicated coeliac outpatient clinic from January 2010 to May 2019 identified 59 patients who were undergoing treatment with an ARB. Only those with CD confirmed by serology (both anti-TTG + ve and EMA + ve) and histopathology (Marsh criteria ≥ 1) and on a GFD were included. Patients without a bone fide diagnosis of CD, referred to the clinic specifically for assessment of possible ARB-e were excluded. Patients who may have been on an ARB at the time of diagnosis of CD irrespective of the anti-TTG titre were also excluded (Figure 1). Therefore, only those with a definitive diagnosis of CD prior to ARB initiation were included.

Data collection

Coeliac serology (anti-TTG and EMA) and histopathology (Marsh grade) of all included patients were reviewed to confirm the diagnosis of CD according to current international guidelines. Information from patients’ most recent outpatient clinic encounter including anti-TTG titre, biochemical tests, and histopathology was included for analysis. Symptom review including diarrhoea, weight loss, abdominal pain as well as surrogate markers of small bowel absorption (Vitamin D, Iron, Calcium, and Haemoglobin) was also recorded. The presence of mucosal healing (Marsh 0) and non-healing mucosa (Marsh ≥1) were compared across the two groups.

Control group

Patients were age and sex-matched in a 1:2 ratio with CD patients selected from a prospectively managed database who were never exposed to ARBs. Controls were also selected to match the ARB group in terms of disease duration and compliance to the GFD.

Olmesartan sub-group

The available data in published case reports and case series to date suggests a more pronounced enteropathy with olmesartan and negative coeliac serology when compared with other ARBs. We, therefore, performed a sub-group analysis of our coeliac patients taking olmesartan and compared this with other ARBs as well as controls to determine whether this sub-group might bias the overall comparison between subjects and controls.

Statistical analysis

Descriptive statistics were used to calculate measures of central tendency in the form of means for continuous variables (e.g., age, duration symptoms, and disease activity biomarkers) and proportions for categorical variables (e.g., compliance with GFD, presence of symptoms, coeliac serology, Marsh staging index). Distribution of continuous variables were expressed in the form of standard deviation. A comparison between groups (ARB vs. control, olmesartan vs. control and olmesartan vs. non-Olmesartan ARBs) was performed using a chi-square test for categorical variables and two sample unpaired t-test for continuous variables given the normal distribution of values. Two-sided testing was performed given the potential bidirectional nature of association understudy and results were considered significant with a p-value <0.05.

Ethics

This study was approved by the Galway University Hospital Clinical Research Ethics Committee on the 1st of December 2020 (Ref: C.A. 2518). Written, informed consent was not required for this study by the Ethics committee. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research committee.

RESULTS

Demographics

A total of 40/1142 patients (0.52%) were identified (26 female, 63%) who met the inclusion criteria of a confirmed diagnosis of CD and subsequent treatment with an ARB. Olmesartan accounted for 25%
of all ARBs (n = 10). Non-olmesartan ARBs included telmisartan (n = 13, 33%), valsartan (n = 6, 15%), losartan (n = 8, 20%) and candesartan (n = 3, 7%). There were 82 patients included in the control group (52 female, 63%). Demographic data and reported compliance with GFD were similar in both groups (Table 1), while disease duration was longer in the control group (13.3 vs. 8.2 years).

**Symptoms**

Persistent symptoms were reported in 25% (n = 10/40) of the ARB group compared with 9% (n = 7/82) of controls (p = 0.018) (Figure 2). There was no difference in symptoms reported between olmesartan (20%) and other ARBs (27%) (p = 0.19).

**Marsh grade**

Follow up histopathology was available for analysis in 75% (n = 30) and 73% (n = 60) in the ARB and control group respectively. The mean time from diagnosis to the most recent histological follow-up was 39.9 months (SD 25.3) for the ARB group and 48.4 months (SD 32.6) for the control group. Complete mucosal healing (Marsh 0) was present in 36% (n = 11/30) in the ARB group compared to 55% in the control group (n = 33/60) (p = 0.04) (Figure 3). Incomplete mucosal healing or persistent villous atrophy (Marsh ≥1) was reported in 63% (n = 19/30) in the ARB group in contrast with the control group (45%, n = 27/60) despite not reaching statistical significance (p = 0.18).

**Coeliac serology**

Anti-TTG titres were positive in 6% (n = 5/82) of the control group compared with 10% (n = 4/40) of those taking ARBs (p = 0.42). The mean duration of GFD at the time of most recent anti-TTG

---

**TABLE 1** Demographic data and disease characteristics of included patients

|                      | Olmesartan (n = 10) | Other ARBs (n = 30) | P value (groups 1 vs 2) | All ARBs (n = 40) | Control (n = 82) | P value (groups 1 vs 4) | P value (groups 3 vs 4) |
|----------------------|----------------------|---------------------|-------------------------|-------------------|------------------|-------------------------|-------------------------|
| Mean age (years)     | 62.8 (SD 16.49)      | 67.3 (SD 10.82)     | 0.37                    | 66.2 (SD 12.04)   | 66.2 (SD 12.3)   | 0.42                    | 1.0                     |
| Mean duration of disease (years) | 6.5 (SD 3.98) | 9.9 (SD 11.03) | 0.35 | 8.2 (SD 8.66) | 13.3 (SD 9.42) | 0.02 | 0.07                     |
| Compliance GFD (%)   | 60 (6/10)            | 53 (16/30)          | 0.7                     | 55 (22/40)        | 56 (46/82)       | 0.72                    | 0.26                     |
| Symptoms (%)         | 0 (2/10)             | 13 (4/30)           | 0.23                    | 10 (4/40)         | 6 (5/82)         | 0.42                    | 0.42                     |
| Positive coeliac serology- not index (%) | 0 (0/10) | 13 (4/30) | 0.23 | 10 (4/40) | 6 (5/82) | 0.42 | 0.42                     |
| Marsh staging (%)    | 20 (2/10)            | 30 (9/30)           | 0.54                    | 36 (11/30)        | 55 (33/60)       | 0.1                     | 0.04                     |
|                      | 10 (1/10)            | 13 (4/30)           | 0.8                     | 16 (5/30)         | 8 (5/60)         | 1.0                     | 0.62                     |
|                      | 50 (5/10)            | 30 (9/30)           | 0.54                    | 48 (14/30)        | 37 (22/60)       | 0.18                    | 0.13                     |
|                      | 20 (2/10)            | 27 (8/30)           |                         | 25 (10/40)        | 27 (22/82)       |                         |                         |
| HB                   | 13.2 (SD 2.39)       | 12.7 (SD 1.48)      | 0.44                    | 12.8 (SD 1.74)    | 12.8 (SD 1.44)   | 0.45                    | 1.00                     |
| Vitamin D            | 44.2 (SD 21.8)       | 69.9 (SD 27.6)      | 0.01                    | 67 (SD 27.0)      | 65.6 (SD 19.3)   | 0.0015                  | 0.74                     |
| Iron                 | 14.8 (SD 12.73)      | 13.5 (SD 10.05)     | 0.74                    | 13.78 (SD 7.46)   | 13.8 (SD 7.77)   | 0.72                    | 0.98                     |
| Calcium              | 2.35 (SD 0.78)       | 2.36 (SD 0.08)      | 0.94                    | 2.36 (SD 0.08)    | 2.36 (SD 0.09)   | 0.9                     | 1.0                      |

Notes: Marsh n/a—histology not available. These were put in bold/italics to signify p values. The p values in old were statistically significant. The values in red were highlighted as statistically significant values (i.e., values <0.05).

Abbreviations: ARBs, angiotensin receptor blockers; GFD, gluten-free diet; HB, haemoglobin.
assessment was 57.3 months (SD 39.9) for the ARB group and 61.4 months (SD 38.6) for the control group. Further analysis revealed negative anti-TTG serology in all patients taking olmesartan \((n = 10, p = 0.42)\) as well as those taking losartan \((n = 8)\) and valsartan \((n = 6)\) (Table 2), while positive anti-TTG serology was identified in a subset of those taking telmisartan \((n = 3/13)\) and candesartan \((n = 1/3)\).

**Surrogate markers of absorption**

Surrogate markers of small bowel absorption were comparable across the groups, except for 25 hydroxyvitamin D3 which was lower \(44.2 \text{ nmol/L}\) in the olmesartan group compared to other ARBs \(69.9 \text{ nmol/L}\) \((p = 0.01)\) and controls \(65.5 \text{ nmol/L}\) \((p = 0.0015)\) (Table 1).

**DISCUSSION**

This study evaluates the effects of ARB exposure in patients with CD following a gluten-free diet. We sought to determine whether ARB-e may represent a new and important consideration in the investigation of non-responsive or non-healing CD. Prior reports of ARB-e as a distinct clinical entity mimicking that of CD suggested a higher incidence in HLA DQ2/DQ8 positive individuals but heretofore data on the impact of ARBs in established CD was unknown. We have shown that ARB exposure is associated with persistent mucosal damage and this appears to be a class effect rather than that confined to olmesartan induced enteropathy.

CD patients exposed to ARBs report increased symptoms of abdominal pain, weight loss and diarrhoea compared to controls \(25\% \text{ vs. } 9\%, p = 0.018\). Moreover, ARB exposed patients have lower rates of mucosal healing with only 36% of such patients achieving a Marsh grade of 0 compared with 55% of controls. Increased rates of ongoing mucosal injury, as defined by Marsh \(\geq 1\), were also recorded in the ARB exposed group. Failure to reach statistical significance was likely affected by the small sample size but such findings suggest the entity of an additional ARB-e or an aggravation of the coeliac related enteropathy, as a result of exposure to ARB.

Interestingly, this injury does not appear to be driven by a TTG induced response as evidenced by the low (telmisartan/candesartan) or negative (olmesartan/losartan/valsartan) TTG serology recorded.

**FIGURE 3** Comparison of Marsh Grade in angiotensin receptor blockers and Control Groups

**TABLE 2** Clinical, serological and histological features for each class of ARB

|                   | Olmesartan \((n = 10)\) | Telmisartan \((n = 13)\) | Losartan \((n = 8)\) | Valsartan \((n = 6)\) | Candesartan \((n = 3)\) |
|-------------------|--------------------------|---------------------------|----------------------|------------------------|------------------------|
| Mean age (years) (SD) | 62.8 (16.5)              | 66.4 (11.1)               | 65.3 (11.2)          | 70.2 (13.4)            | 71 (4.6)               |
| Female            | 5                        | 9                         | 5                    | 4                      | 2                      |
| Mean duration of disease (years) (SD) | 6.5 (3.98)              | 9.76 (12.5)               | 11 (12.8)            | 10.5 (9.6)             | 7.7 (1.5)              |
| Compliance GFD (%) | 60                       | 76                        | 25                   | 50                     | 33                     |
| Symptoms (%)      | 20                       | 30                        | 38                   | 16                     | 0                      |
| Positive TTG (%)  | 0                        | 23                        | 0                    | 0                      | 33                     |
| Marsh staging (%) | 20                       | 23                        | 25                   | 50                     | 33                     |
| 1                 | 10                       | 8                         | 12.5                 | 0                      | 66                     |
| 3                 | 50                       | 46                        | 37.5                 | 0                      | 0                      |
| n/a               | 20                       | 23                        | 25                   | 50                     | 0                      |
| Haemoglobin (g/dl) | 13.2 (2.4)               | 12.6 (1.4)                | 13.4 (1.4)           | 12.4 (1.5)             | 11.4 (1.9)             |
| 25 (OH) Vitamin D (nmol/L) (SD) | 44.2 (21.8)              | 71.3 (29.1)               | 64.8 (25.4)          | 85.2 (14.8)            | 52.3 (42.2)            |
| Iron (mol/L) (SD)  | 14.8 (8.45)              | 12.3 (3.85)               | 14.8 (10.7)          | 15.3 (8.45)            | n/a                    |
| Calcium (mmol/L) (SD) | 2.35 (0.08)             | 2.36 (0.09)                | 2.36 (0.06)          | 2.38 (0.08)            | 2.13 (0.14)            |

Abbreviations: ARBs, angiotensin receptor blockers; GFD, gluten-free diet; TTG, anti-tissue transglutaminase.
in these patients. Moreover, the rate of positive serology was equivalent to that in the control group (6% and 10%, respectively). This would suggest that a different mechanism of action is at play, similar to that observed in the non-coeliac population.

It is important to recognise the possibility of drug-induced enteropathy at an early stage in the investigation of non-responsive CD as withdrawal of the offending medication should lead to prompt resolution of symptoms and mucosal healing, thus avoiding escalation of investigations and inappropriate initiation of a treatment algorithm. The evaluation of ARB related non-responsive CD should always be considered, particularly in elderly coeliac patients, who are the most commonly exposed to such a class of anti-hypertensive drug.30

The possibility that inadvertent gluten contamination could account for variations in symptoms, serological markers and histological changes is inherent in any study of disease activity in CD. Indeed, this has been particularly challenging in the definition of primary endpoints in clinical trials assessing novel pharmacological agents, with no single measure of disease activity widely accepted.31 In this context, validated patient reported outcomes (e.g., symptoms based) have been increasingly considered as acceptable standards for evaluating disease activity in CD.31,32 Strict compliance with a GFD in this study was comparable across the two groups and consistent with levels of reported compliance in other studies.33 We, therefore, posit the risk of gluten contamination was equivalent in both groups and unlikely to account for variation observed.

There are some limitations to the study that should be reported. The sample size in this study, while relatively small, is considerable given the obscure and rare nature of the interaction studied. Nonetheless, the effect of such a small sample size on statistical significance must be acknowledged. Indeed, the retrospective nature of the study does introduce the possibility of selection and information bias, which cannot be overcome with a larger sample size. A validated questionnaire to evaluate compliance with GFD was not employed, rather individual recall of exposure was relied upon which in itself has its inherent risks. This however was similar across the two groups.

CONCLUSION

This retrospective observational case-control study reports the confounding effect of ARB use on the interpretation of symptoms and lack of mucosal healing in established coeliac patients. We demonstrate that ARB exposed coeliac patients are more likely to have persistent symptoms and ongoing mucosal injury than their age and sex-matched non-exposed coeliac controls. Furthermore, this study confirms a class effect rather than a phenomenon unique to olmesartan. This observation appears to be independent of TTG mediated injury, akin to that reported in non-coeliac populations. Screening for ARB exposure is paramount during the assessment of non-responsive CD. Indeed, we propose drug withdrawal and alternative anti-hypertensive drug use in such cases of ‘pseudo-refractory’ CD.

ACKNOWLEDGEMENT
The authors wish to acknowledge the ongoing commitment to care by all the staff involved in the coeliac clinic at Galway University Hospital, as well as the contribution of patients to research. There was no source of funding for this research study.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Neil O’Morain https://orcid.org/0000-0003-2542-9455
Eileen Shannon https://orcid.org/0000-0003-2391-8757
Hilary Leeson https://orcid.org/0000-0002-1692-9207

REFERENCES
1. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu T-T, et al. Severe sprue-like enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87 (8):732–8.
2. Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019;7 (3):162–7.
3. Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review—sprue-like enteropathy associated with Olmesartan. Aliment Pharmacol Ther. 2014;40:16–23.
4. Choi EYK, McKenna B. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch Pathol Lab Med. 2015;139 (10):1242–7.
5. Sáez González E, Díaz Jaime FC, Del Val Antoñana A. Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use. Rev Esp Enferm Dig. 2016;108 (10):685–6.
6. Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103–9.
7. Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016;65:1664–9.
8. Uehara T, Ikusaka M, Ohira Y, Noda K, Suzuki S, Shikino K, et al. Olmesartan-induced enteropathy manifesting as Wernicke-Korsakoff Syndrome. Intern Med. 2016;55:24–3678.
9. Talbot G. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc. 2012;87:1231–2.
10. Marild K, Lebwohl B, Green P, Murray JA, Ludvigsson JF. Blockers of angiotensin other than olmesartan in patients with villous atrophy—a nationwide case-control study. Mayo Clin Proc. 2015;90 (6):730–7.
11. Negro A, De Marco L, Cegaro V, Santi R, Boni MC, Zanelli M. A case of moderate sprue-like enteropathy associated with telmisartan. J Clin Med Res. 2017;9 (12):1022–5.
12. Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol. 2015;49(9):794.

13. Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J. 2015;2(2):92–4.

14. Van Gils T, Robijn R, Bouma G, Neefjes-Borst EA, Mulder CJJ. A pitfall in suspected (refractory) celiac disease: losartan-induced enteropathy. Am J Gastroenterol. 2017;112(11):1754–5.

15. Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015;51(2):87–8.

16. Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy—is there any class effect? Aliment Pharmacol Ther. 2014;40:569–70.

17. Lagana SM, Braunstein ED, Arguelles-Grande C, Bhagat G, Green PHR, Lebwohl B. Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. J Clin Pathol. 2015;68:29–32.

18. Ghaith J, Raslan IA, Szigayi A, Alameldin M. Case of olmesartan-associated enteropathy and transient positive antitissue transglutaminase serology. BMJ Case Rep. 2018: e225518.

19. Kulai T, Arnason T, McIntosh D, Igoe J. Duodenal villous atrophy in a TTG-negative patient taking olmesartan: a case report and review of the literature. Can J Gastroenterol Hepatol. 2016:16.

20. Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. J Gastroenterol. 2013;19(40):6928–30.

21. Burbure N, Lebwohl B, Arguelles-Grande C, Green PHR, Bhagat G, Lagana S. Olmesartan associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34.

22. Tran TH, Li H. Olmesartan and drug-induced enteropathy. Pharm Ther. 2014;39(1):47–50.

23. Lebwohl B, Ludvigsson JF. Editorial: sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers—the plot thickens. Aliment Pharmacol Ther. 2014;40:1245–6.

24. Marietta EV, Nadeau AM, Cartee AK, Singh I, Rishi A, Choung RS, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42:1303–14.

25. Esteve M, Temiño R, Carrasco A, Batista L, Del Val A, Blé M, et al. Potential celiac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Dig Liver Dis. 2016;48(2):154–61.

26. Dong Y-H, Jin Y, Tsacogianis TN, Hsieh M, He P-H, Gagne JJ. Use of olmesartan and enteropathy outcomes: a multi-database study. Aliment Pharmacol Ther. 2018;47:792–800.

27. DeGaetani M, Tennyson C, Lebwohl B, Lewis SK, Abu Daya H, Arguelles-Grande C, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647–53.

28. Cartee AK, Reyes Genere JP, Oxentenko AS. New onset villous atrophy in a patient with celiac disease. Gastroenterology. 2018;155(4):988–9.

29. Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63:1210–28.

30. Tortora R, Zingone F, Rispo A, Bucci C, Capone P, Imperatore N, et al. Coeliac disease in the elderly in a tertiary centre. Scand J Gastroenterol. 2016;51(10):1179–83.

31. Ludvigsson JF, Ciacci C, Green PH, Kaukinen K, Korponay-Szabo IR, Kurppa K, et al. Outcome measures in coeliac disease trials: the Tampere recommendations. Gut. 2018;67:1410–24.

32. Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang C-M, Parker C, et al. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2018;67:61–9.

33. Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther. 2009;30:315–30.

How to cite this article: O’Morain N, Shannon E, McManus J, Warner V, Leeson H, O’Donovan H, et al. Coeliac disease enteropathy and symptoms may be aggravated by angiotensin receptor blockers in patients on a gluten-free diet. United European Gastroenterol J. 2021;1–7. https://doi.org/10.1002/ueg.12117